Stylianos Michalakis

Title: Innovations by Stylianos Michalakis

Introduction

Stylianos Michalakis is a prominent inventor based in Munich, Germany. He has made significant contributions to the field of gene therapy, particularly in the treatment of retinal diseases. With a total of 6 patents, his work has the potential to impact the lives of many individuals suffering from genetic disorders.

Latest Patents

One of his latest patents focuses on gene therapy for the treatment of CNGB1-linked retinitis pigmentosa. This invention involves a polynucleotide that comprises a human photoreceptor-specific promoter element, a core promoter, and at least one transgene. Additionally, the invention includes a plasmid, a viral vector, and a pharmaceutical composition for use as a medicament, specifically targeting diseases of the retina. Another notable patent involves adeno-associated virus (AAV) vectors, which include an insertion of at least 6-8 amino acids between specific positions. This invention also encompasses the use of AAVs as a medicament and their application in transducing the nucleus of retinal cells.

Career Highlights

Throughout his career, Michalakis has worked with various companies, including Eyeserv GmbH. His innovative approaches and research have positioned him as a key figure in the field of gene therapy.

Collaborations

He has collaborated with notable individuals such as Martin Biel and Mathias Seeliger, contributing to advancements in his research and inventions.

Conclusion

Stylianos Michalakis continues to be a driving force in the realm of gene therapy, with his inventions paving the way for new treatments for retinal diseases. His work exemplifies the impact of innovation in medical science.